India Dilip Surana of family-run Indian generics giant Micro Labs talks company performance, the evolution of the Indian pharma market, and strategy moving forward. Last year Micro Labs moved up in the rankings. How satisfied are you with the company’s performance in 2010? The company performed satisfactorily last year, showing good…
Agendia Agendia has experienced remarkable growth in the seven years since you founded the company. In 2009 you expanded the company’s Amsterdam facilities and, in 2010, you doubled the size of its U.S. facilities. Why this drastic expansion, especially over the last two years? Agendia continues to grow at a rapid…
Astellas Pharma India Pvt. Ltd. When Astellas announced to expand its presence in India in 2009, you were already speaking of the company’s long commitment and solid relationship with India. Can you elaborate on these historical ties and how important it was to set up your India operations at that time? Since the former Fujisawa…
Quintiles India Quintiles first established its operations in India in 1997, which was a very early stage in clinical research. What have been the main changes undergone by the country since then? When Quintiles established operations in India in 1997 via a joint venture, it redefined the CRO industry. Prior to this,…
Novartis India Right after you started heading the India operations roughly 15 years ago, you had to oversee one the biggest mergers in the industry at that time. How challenging was that moment for you? Any merger has its set of challenges and opportunities, and I think you will always look more…
Nycomed India While we have seen many MNCs becoming increasingly interested in India, the story of Nycomed has been quite unique. Rather than starting off with marketing and sales offices, India was chosen as the first global R&D centre outside of Europe. First of all, what sparked this early interest in Indian…
Roche Products (India) Pvt. Ltd. There is no doubt that India has become a country of rising opportunities. Can you first elaborate how important India has become for the Group worldwide? India has become very important, mainly because of the rising middle class population in the country. One of the problems with India however, is…
Lonza India Pvt. Ltd You have already publicly announced that, despite being late in India, Lonza has been increasingly looking into expanding in the Indian market. First of all, what do you think sparked the increasing interest in this market? The driving factor was the fact that the Indian consumer market has been increasing.…
Boehringer Ingelheim India Pvt. Ltd. Before moving into the company’s strategy, can you give our readers an idea of what role Boehringer Ingelheim India plays within the Group’s worldwide operations? Within the Boehringer Ingelheim Group, there are the mature and emerging markets for the prescription medicines. Within this structure, India falls into the emerging markets…
Pfizer Limited India To start off, can you tell us how you have seen the pharmaceutical industry developing in India? Has the perception of India by big pharma changed over the years? First of all, if you compare the growth rates of MNCs in India over the last 5 years in the pharmaceutical…
GlaxoSmithKline Pharmaceuticals Limited - Ind A catalyst of India’s shifting industry dynamics has been the sector’s M&A activity. We already saw majors such as Piramal going to Abbott and Ranbaxy to Daiichi-Sankyo… And while Andrew Witty has publicly announced to pursue acquisitions here, growth has largely been organically. Is it too late for GSK to…
Glenmark Glenmark may be poised to release India’s first novel drug, from the in-licensed, anti-diarrheal molecule Crofelemer. Crofelemer has successfully complete Phase III trials, and you are readying to release it across 140 countries. What stage of the process are you in? When will we see India’s first novel drug in…
See our Cookie Privacy Policy Here
